Up next

DCAT Week ’18: CDMOs, CMOs, and Suppliers: Expansion Roundups

What have been the key developments from contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), and other suppliers and companies supporting pharmaceutical /biopharmaceutical development and manufacturing thus far in 2018?

This special issue of DCAT Value Chain Insights highlights key developments from January 2018 to April 3, 2018 of DCAT member companies making the news. 

Chemical/Chemical API Manufacturing

Biologics Manufacturing

Formulation/Drug Product Manufacturing

Packaging

General

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

Blockbuster Contenders: The Class of 2026

By
What new products, recently or expected to launch in 2026, show blockbuster potential or will be transformative in key therapeutic areas? A look at the companies and products rising to the top of the class. 

CDMOs Roll Out Expansions for Parenteral Drugs

By
The global injectables drugs market is projected for strong growth, driven by demand in biologics and specialty therapeutics. In response, CDMOs/CMOS are expanding production capacity. What are the latest expansions?

Big Pharma Outlook: CEOs Making the Moves

By
As the industry moves further into 2026, what are larger issues impacting industry and company performance? .A view from the C-suite.

Industry Radar: What’s Next in US Drug Pricing

By
A bevy of news on the US drug pricing front: the debut of TrumpRx, a direct-to-patient drug purchasing channel, continued policy moves to most favored drug nation pricing, reforms of PBMs, and the latest in IRA